A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Evaluate the Efficacy and Safety of RZ358 in Patients with Congenital Hyperinsulinism

drug protocol number
RZ358-301
drug sponsor
Rezolute Inc
drug study
RZ358
drug trial site
King Abdulaziz Medical City NG (Riyadh)
drug status
Ongoing
drug phase